vs

Side-by-side financial comparison of WESTPORT FUEL SYSTEMS INC. (WPRT) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.5M, roughly 1.1× WESTPORT FUEL SYSTEMS INC.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -274.8%, a 350.5% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-6.4M).

Westport Innovations is a company that develops alternative fuel, low-emissions technologies to allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), hydrogen and biofuels such as landfill gas. Headquartered in Vancouver, British Columbia, Canada, where the company was founded, Westport also has facilities in France, Sweden, Italy, China, Australia and the United States.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

WPRT vs XLO — Head-to-Head

Bigger by revenue
XLO
XLO
1.1× larger
XLO
$13.7M
$12.5M
WPRT
Higher net margin
XLO
XLO
350.5% more per $
XLO
75.7%
-274.8%
WPRT
More free cash flow
XLO
XLO
$4.4M more FCF
XLO
$-2.1M
$-6.4M
WPRT

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
WPRT
WPRT
XLO
XLO
Revenue
$12.5M
$13.7M
Net Profit
$-34.3M
$10.4M
Gross Margin
6.7%
Operating Margin
-8.1%
-86.5%
Net Margin
-274.8%
75.7%
Revenue YoY
-11.4%
Net Profit YoY
-690.4%
179.1%
EPS (diluted)
$-1.98
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
WPRT
WPRT
XLO
XLO
Q4 25
$13.7M
Q3 25
$19.1M
Q2 25
$12.5M
$8.1M
Q1 25
$2.9M
Q3 24
$4.9M
Q2 24
$14.1M
Net Profit
WPRT
WPRT
XLO
XLO
Q4 25
$10.4M
Q3 25
$-16.3M
Q2 25
$-34.3M
$-15.8M
Q1 25
$-13.3M
Q3 24
$-3.9M
Q2 24
$5.8M
Gross Margin
WPRT
WPRT
XLO
XLO
Q4 25
Q3 25
Q2 25
6.7%
Q1 25
Q3 24
13.6%
Q2 24
16.7%
Operating Margin
WPRT
WPRT
XLO
XLO
Q4 25
-86.5%
Q3 25
-10.1%
Q2 25
-8.1%
-177.7%
Q1 25
-472.7%
Q3 24
-43.9%
Q2 24
-54.9%
Net Margin
WPRT
WPRT
XLO
XLO
Q4 25
75.7%
Q3 25
-85.4%
Q2 25
-274.8%
-196.0%
Q1 25
-452.7%
Q3 24
-79.3%
Q2 24
41.2%
EPS (diluted)
WPRT
WPRT
XLO
XLO
Q4 25
$-3.74
Q3 25
$-0.11
Q2 25
$-1.98
$-0.16
Q1 25
$-0.18
Q3 24
$-0.22
Q2 24
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
WPRT
WPRT
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$6.1M
$137.5M
Total DebtLower is stronger
$977.0K
Stockholders' EquityBook value
$108.9M
$35.3M
Total Assets
$272.1M
$154.7M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
WPRT
WPRT
XLO
XLO
Q4 25
$137.5M
Q3 25
$103.8M
Q2 25
$6.1M
$121.6M
Q1 25
$89.1M
Q3 24
Q2 24
Total Debt
WPRT
WPRT
XLO
XLO
Q4 25
Q3 25
Q2 25
$977.0K
Q1 25
Q3 24
Q2 24
Stockholders' Equity
WPRT
WPRT
XLO
XLO
Q4 25
$35.3M
Q3 25
$-8.1M
Q2 25
$108.9M
$7.1M
Q1 25
$10.7M
Q3 24
$149.3M
Q2 24
$151.5M
Total Assets
WPRT
WPRT
XLO
XLO
Q4 25
$154.7M
Q3 25
$133.7M
Q2 25
$272.1M
$133.8M
Q1 25
$103.7M
Q3 24
Q2 24
Debt / Equity
WPRT
WPRT
XLO
XLO
Q4 25
Q3 25
Q2 25
0.01×
Q1 25
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
WPRT
WPRT
XLO
XLO
Operating Cash FlowLast quarter
$-5.6M
$-2.0M
Free Cash FlowOCF − Capex
$-6.4M
$-2.1M
FCF MarginFCF / Revenue
-51.6%
-15.3%
Capex IntensityCapex / Revenue
6.6%
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
WPRT
WPRT
XLO
XLO
Q4 25
$-2.0M
Q3 25
$-17.5M
Q2 25
$-5.6M
$-14.5M
Q1 25
$29.0M
Q3 24
$-11.7M
Q2 24
$1.5M
Free Cash Flow
WPRT
WPRT
XLO
XLO
Q4 25
$-2.1M
Q3 25
Q2 25
$-6.4M
$-14.9M
Q1 25
$29.0M
Q3 24
$-11.9M
Q2 24
$262.0K
FCF Margin
WPRT
WPRT
XLO
XLO
Q4 25
-15.3%
Q3 25
Q2 25
-51.6%
-184.0%
Q1 25
988.3%
Q3 24
-243.4%
Q2 24
1.9%
Capex Intensity
WPRT
WPRT
XLO
XLO
Q4 25
0.7%
Q3 25
0.0%
Q2 25
6.6%
5.0%
Q1 25
0.8%
Q3 24
3.8%
Q2 24
8.9%
Cash Conversion
WPRT
WPRT
XLO
XLO
Q4 25
-0.19×
Q3 25
Q2 25
Q1 25
Q3 24
Q2 24
0.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons